Skip to content

DELP randomized open-label study in vitro treatment of lipid separation within 48 hours of onset of acute ischemic stroke

DELP randomized open-label study in vitro treatment of lipid separation within 48 hours of onset of acute ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15007089
Enrollment
Unknown
Registered
2015-09-18
Start date
2015-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Sponsors

The General Hospital of Shenyang Military
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. patients aged 18-80 years old; 2. Within 48 hours of onset; 3. curtain ischemic stroke; The clinical neurological deficit: NIHSS score before the cycle by 6 to 22 points; 5. blood pressure <=180/110mmHg; 6. A head CT imaging changes without bleeding; 7. At the first onset or the last onset did not leave again onset of paralysis andother complications, anddoes not affect this NIHSS score, previous onset of this admission mRS score <=1 points; 8. signed informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. serious heart, liver, kidney disease (serum bilirubin, alanine aminotransferase, aspartate aminotransferase 1.5 times higher than normal, blood urea nitrogen, creatinine 1.5 times higher than normal) person; 2. uncontrolled hypertension (blood pressure> 180/110mmHg); 3. hemorrhagic stroke; 4. Patients can not cope with severe disturbance of consciousness in patients with stroke (NIHSS score> 23 points), psychosis, dementia andthe like; 5. atrial fibrillation; 6. Pregnant women, lactation; 7. Plan thrombolytic treatment of patients; 8. used after the onset of neuroprotective agents (such as edaravone, ganglioside, maleic acid cinepazide PL); 9. Because of the presence of comorbid life expectancy of less than six months; Within 10.3 months who are participating in other clinical trials; 11. venipuncture site have infected; 12. Past heparin, calcium allergy; 13. less than 50,000 platelets, coagulation severe abnormalities; 14. Hypoproteinemia; 15. refused to participate.

Design outcomes

Primary

MeasureTime frame
90 days mRS score;

Countries

China

Contacts

Public ContactHuisheng Chen
chszh@aliyun.com+86 13352452086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026